Immutep IMMP
NASDAQ IMMP
$0.36 -0.01 (-2.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Immutep (IMMP) Common Equity (2011 - 2026)

Immutep's (IMMP) quarterly Common Equity came in at $43.6 million in Q2 2026, down 52.55% on a YoY basis from $92.0 million in Q2 2025, and down 32.78% quarter-over-quarter from $64.9 million in Q4 2025.

Analysis

Immutep (IMMP) Common Equity (2011 - 2026) Analysis & Trends

Immutep (IMMP) has reported Common Equity for 16 consecutive years, with $43.6 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Common Equity fell 52.55% year-over-year to $43.6 million; the trailing twelve-month figure through Jun 2026 stood at $43.6 million (down 52.55% YoY), and the FY2026 full-year result was $43.6 million, down 52.55% from the prior year.
  • Common Equity eased to $43.6 million in Q2 2026 per IMMP's latest filing, from $64.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $124.9 million in Q2 2024 and bottomed at $43.6 million in Q2 2026.
  • Historically, Common Equity has averaged $80.3 million across 5 years, with a median of $75.3 million in 2023.
  • The sharpest annual moves came in 2024 and 2026: Common Equity surged 49.82% in 2024, then tumbled 52.55% in 2026.
  • Over 5 years, Common Equity stood at $50.4 million in 2022, then soared by 49.41% to $75.3 million in 2023, then jumped by 49.82% to $112.8 million in 2024, then slumped by 42.43% to $64.9 million in 2025, then slumped by 32.78% to $43.6 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods registered $43.6 million, $64.9 million, and $92.0 million for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 11.69 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 11.83 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 20.25 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 31.71 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 8.42 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 6.76 Bn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 1.35 Bn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 18.85 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 4.92 Bn
10 Immutep 51.68 Mn 51.68 Mn - 43.65 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 43.65 Mn
Dec 31, 2025 64.93 Mn
Jun 30, 2025 91.99 Mn
Dec 31, 2024 112.79 Mn
Jun 30, 2024 124.90 Mn
Dec 31, 2023 75.28 Mn
Jun 30, 2023 91.21 Mn
Dec 31, 2022 50.39 Mn
Jun 30, 2022 67.38 Mn
Dec 31, 2021 79.32 Mn
Jun 30, 2021 56.42 Mn
Dec 31, 2020 44.36 Mn
Jun 30, 2020 21.83 Mn
Dec 31, 2019 19.15 Mn
Jun 30, 2019 17.08 Mn
Jun 30, 2018 25.38 Mn
Dec 31, 2017 20.86 Mn
Jun 30, 2017 19.93 Mn
Mar 31, 2017 21.56 Mn
Dec 31, 2016 31.25 Mn